ACCELERATED HYPERFRACTIONATED DAY DOSE CHART CHEMORADIATION TREATMENT OF PATIENTS WITH CANCER OF OROPHARYNX AND ORAL CAVITY
Abstract
The main treatment failures of cancer of the oropharynx and oral cavity are associated with the treatment of advanced (III–IV) stages of the disease, incidence of which is extremely high. The treatment toxicity increases and quality of life reduces with increasing aggressiveness of anticancer therapy. Therefore, the search for conservative treatment methods in order to achieve optimal treatment efficacy remains relevant. The study included 233 patients with primary cancer of the oropharynx and oral cavity, who underwent concurrent chemoradiotherapy with accelerated hyperfractionated radiation and standard radiation therapy. In patients who received chemoradiotherapy with accelerated hyperfractionated radiation in the regimens of 1 Gy + 1.5 Gy and 1 Gy+2 Gy with a 4–6 hour interval, 60 Gy total dose, the objective response rate (complete + partial regressions) was significantly higher than that observed in patients who received the standard radiotherapy (97.8; 100 and 61.9 %, respectively). Severe mucositis (grade 3) was observed in 40.5 and 77.8 % of patients treated with accelerated hyperfractionated radiation in the regimens of 1 Gy+1.5 Gy and 1 Gy+2 Gy, respectively compared to 52.7% of patients treated with the standard radiotherapy (p<0.05) Late radiation-induced damage to normal tissues and organs in the radiation field occurred in 8.9; 10.8 and 20.2 %, respectively (p>0.05). Immediate treatment results and survival analysis showed that chemoradiotherapy with accelerated hyperfractionated radiation was superior to standard radiation therapy without increasing the late local toxicity. All patients completed the planned course of treatment, despite the high rate of grade 3 mucositis in the 1 Gy + 2 Gy dose regimen.
About the Authors
M. U. Radzhapova
A.F. Tsyba Medical Radiological Research Center affiliated to P.A. Gertsen Moscow Cancer Research Institute, Obninsk
Russian Federation
Radzhapova Maria Urunovna, MD, PhD, Leading Researcher, Radiation Therapy Department
Russian Federation
Radzhapova Maria Urunovna, MD, PhD, Leading Researcher, Radiation Therapy Department
L. A. Gulidov
A.F. Tsyba Medical Radiological Research Center affiliated to P.A. Gertsen Moscow Cancer Research Institute, Obninsk
Russian Federation
Gulidov Igor Alexandrovich, MD, Professor, Head of External Beam Radiation Therapy Department
Russian Federation
Gulidov Igor Alexandrovich, MD, Professor, Head of External Beam Radiation Therapy Department
Yu. S. Mardynskiy
A.F. Tsyba Medical Radiological Research Center affiliated to P.A. Gertsen Moscow Cancer Research Institute, Obninsk
Russian Federation
Mardyntsky Yuri Stanislavovich, MD. Professor, Associate Member of RAS, Head of Radiation Therapy Department
Russian Federation
Mardyntsky Yuri Stanislavovich, MD. Professor, Associate Member of RAS, Head of Radiation Therapy Department
D. Yu. Semin
A.F. Tsyba Medical Radiological Research Center affiliated to P.A. Gertsen Moscow Cancer Research Institute, Obninsk
Russian Federation
Semin Dmitriy Yuryevich, MD, DSc, Radiosurgery Department
Russian Federation
Semin Dmitriy Yuryevich, MD, DSc, Radiosurgery Department
References
1. Alieva S.B. Chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck // Prakticheskaya onkologiya. 2008. Vol. 9, № 1. P. 27–30. [in Russian]
2. Alieva S.B., Romanov I.S., Podvyaznikov S.O., Zaderenko I.A., Tjuljandin S.A. Efficacy of the induction chemotherapy using docetaxel, cisplatin and 5-FU and subsequent simultaneous chemoradiotherapy in the treatment of cancer of the oral cavity and pharynx stage III–IV // Opukholi golovy i shei. 2011. № 2. P. 14–20. [in Russian]
3. Davydov M.I., Aksel’ E.M. The incidence of malignant neoplasms of the population of Russia and the CIS countries in 2007 // Vestnik RONTs im. N.N. Blokhina RAMN. 2009. Vol. 20, № 3. P. 52–90. [in Russian]
4. Kanaev S.V. Principles and rationale chemoradiation treatment of malignant tumors // Prakticheskaya onkologiya. 2008. Vol. 9 (1). P. 1–8. [in Russian]
5. Kaprin A.D., Starinskiy V.V., Petrova G.V. Condition of the oncological help to the population of Russia in 2012. M., 2013. 231 p. [in Russian]
6. Paches A.I. Tumors of the head and neck. M., 2000. 480 p. [in Russian]
7. Radzhapova M.U., Mardynskiy Yu.S., Gulidov I.A., Medvedev V.S., Semin D.Ju., Ivanova I.N. Chemoradiotherapy with cancer of the oral mucosa and the oropharynx using uneven splitting the daily dose // Sibirskiy onkologicheskiy zhurnal. 2011. Vol. 45. № 3. P. 35–39. [in Russian]
8. Sokurenko V.P., Korytova L.I., Luft A.V., Nekrasova A.V. The toxic burden of aggressive chemoradiation oropharyngeal cancer: state of the problem // Palliativnaya meditsina i reabilitatsiya. 2008. № 1. P. 51–57. [in Russian]
9. Yarmonenko S.P., Vaynson A.A. Radiobiology of human and animal M., 2004. 549 p. [in Russian]
10. Yarmonenko S.P., Konoplyannikov A.G., Vaynson A.A. Clinical radiobiology. M.: Medicine, 1992. 320 p. [in Russian]
11. Jham B.C., da Silva Freire A.R. Oral complications of radiotherapy in the head and neck // Braz. J. Otorhinolaryngol. 2006. Vol. 72 (5). P. 704–708.
12. Jereczek-Fossa B.A., Orecchia R. Radiotherapy-induced mandibular bone complications // Cancer Treat. Rev. 2002. Vol. 28 (1). P. 65–74.
13. Langendijk J.A., Leemans Ch.R., Buter J., Berkhof J., Slotman B.J. The Additional Value of Chemotherapy to Radiotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Meta-Analysis of the Published Literature // J. Clin. Oncol. 2004. Vol. 22 (15). P. 4604–4612.
14. Lefebvre J.L., Lartigau E., Kara A., Sarini J. Oral Cavity, Pharynx and Larynx Cancer // Prognostic Factors in Cancer. 2-nd ed. / Ed. Gospodarowicz M.K. [et al.]. New York: A. John Wiley and sons, 2001. P. 151–166.
15. Madrid C., Abarca M., Bouferrache K. Osteoradionecrosis: An update // Oral Oncol. 2010. Vol. 46 (6). P. 471–474. doi: 10.1016/j.oraloncology.2010.03.017.
16. Mendenhall W.M. Mandibular osteoradionecrosis // J. Clin. Oncol. 2004. Vol. 22 (24). P. 4864–4868.
17. Pignon J.P., Bourhis J., Domenge C., Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of Chemotherapy on Head and Neck Cancer // Lancet. 2000. Vol. 355. (9208). P. 949–955.
18. Trotti A, Bellm L.A., Epstein J.B., Frame D., Fuchs H.J., Gwede C.K., Komaroff E., Nalysnyk L., Zilberberg M.D. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systemic literature review // Radiother. Oncol. 2003. Vol. 66. (3). P. 253–263.
Review
For citations:
Radzhapova M.U., Gulidov L.A., Mardynskiy Yu.S., Semin D.Yu. ACCELERATED HYPERFRACTIONATED DAY DOSE CHART CHEMORADIATION TREATMENT OF PATIENTS WITH CANCER OF OROPHARYNX AND ORAL CAVITY. Siberian journal of oncology. 2015;1(4):19-26. (In Russ.)
Views:
572
Email this article 
